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Background: Marfan syndrome is a rare disease of the connective tissues, affecting multiple organ systems.
Elevated morbidity and mortality in these patients raises the issue of costs for sickness funds and society. To date,
there has been no study analysing the costs of Marfan syndrome from a sickness fund and societal perspective.
Objective: To estimate excess health resource utilisation, direct (non-)medical and indirect costs attributable to
Marfan syndrome from a healthcare payer and a societal perspective in Germany in 2008.
Methods: A retrospective matched cohort study design is applied, using claims data. For isolating the causal effect
of Marfan syndrome on excess costs, a genetic matching algorithm was used to reduce differences in observable
characteristics between Marfan syndrome patients and the control group. 892 patients diagnosed with Marfan
syndrome (ICD-10 Q87.4) were matched from a pool of 26,645 control individuals. After matching, we compared
health resource utilisation and costs.
Results: From the sickness fund perspective, an average Marfan syndrome patient generates excess annual costs of
€2496 compared with a control individual. From the societal perspective, excess annual costs amount to €15,728.
For the sickness fund, the strongest cost drivers are inpatient treatment and care by non-physicians. From the
sickness fund perspective, the third (25–41 years) and first (0–16 years) age quartiles reveal the greatest surplus in
total costs. Marfan syndrome patients have 39% more physician contacts, a 153% longer average length of hospital
stay, 119% more inpatient stays, 33% more prescriptions, 236% more medical imaging and 20% higher average
prescription costs than control individuals. Depending on the prevalence, the economic impact from the sickness
fund perspective ranges between €24.0 million and €61.4 million, whereas the societal economic impact extends
from €151.3 million to €386.9 million.
Conclusions: Relative to its low frequency, Marfan syndrome requires high healthcare expenditure. Not only the
high costs of Marfan syndrome but also its burden on patients’ lives call for more awareness from policy-makers,
physicians and clinical researchers. Consequently, the diagnosis and treatment of Marfan syndrome should begin as
soon as possible in order to prevent disease complications, early mortality and substantial healthcare expenditure.
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Marfan syndrome is a rare, multisystem disease of the con-
nective tissue, affecting multiple organ systems [1]. The
prevalence is estimated at 1–3/10,000 in both male and fe-
male individuals [2]. Although most Marfan syndrome pa-
tients inherit the disease through an autosomal dominant
genetic pathway within the family, 20–30% of new Marfan
syndrome incidents are caused by de novo mutations in in-
dividuals with a previously unaffected family history [3,4].
Pathogenic mutations of the fibrillin-1 (FBN1) gene can
cause dysregulation of transforming growth factor-beta 1
(TGF-b1) signalling, which is a polypeptide growth factor
playing an important role in maintaining the integrity of
the extracellular matrix. Consequently, excessive TGF-b1
causes a weakening of the tissues [5,6].
Marfan syndrome primarily manifests itself through skel-
etal and ocular malformations, diseases of the skin and of
the neurological system as well as lung and cardiovascular
conditions [7,8]. Mitral valve prolapse and aneurysmal dis-
ease of the aorta can be diagnosed in up to 90% [9-11] and
85% [9,12,13] of Marfan syndrome patients respectively.
Aortic root dilation predisposes to severe chronic aortic re-
gurgitation, aortic dissection and rupture [14]. Most sys-
temic manifestations of the Marfan syndrome, especially
cardiovascular ones, may appear in young individuals and
are aggravated with increasing age as they are frequently
the result of weakness in the connective tissue [15-17].
Thanks to the advancement in diagnostic techniques,
such as non-invasive imaging technology and molecular
genetic diagnostics [8,18], as well as refined surgical tech-
niques, such as the remodelling of the aortic root [19-22],
Marfan syndrome can be diagnosed and treated at an early
stage. These developments have contributed to rising life
expectancy from 30 to 60 years within the last three de-
cades [23-25]. However, the high cardiovascular risk may
require life-long prophylactic medication with β-blockers
[24,26], angiotensin-converting enzyme inhibitors (ACE in-
hibitors) [5,8] or angiotensin receptor blockers (ARB)
[7,27], as well as echocardiographic check-ups [28] and, if
necessary, mitral valve replacement/remodelling [29,30]
and aortic root surgery [31]. Permanent skeletal and ocular
surveillance is also mandated [4,32,33].
Owing to increased Marfan syndrome-induced mor-
bidity and mortality, Marfan syndrome patients require
intensified utilisation of healthcare resources. Except for
one study analysing one specific type of reimbursement
of Marfan syndrome treatment in an outpatient clinic
[34], there is no further evidence on the economic im-
pact of Marfan syndrome. The authors are not aware of
any nationwide study that analyses resource use across
all healthcare sectors. Such studies, however, are crucial
in shaping public health policy debates as they represent
a valid economic basis for decision-makers, raise aware-
ness and estimate the extent to which a disease has animpact on (a part of ) society. They are regarded as an
important tool in assisting policy planning, resource al-
location, priority setting and can offer a basis for cost-
effectiveness analyses of healthcare interventions [35].
High disease costs might suggest, for instance, that more
emphasis should be placed on prevention and curative
interventions at an early stage of disease progression.
Consequently, the aim of this paper is to comprehen-
sively and reliably estimate health resource utilisation,
direct (non-)medical and indirect costs attributable to
Marfan syndrome from a sickness fund and a societal
perspective in Germany.
Methods
Study design and study sample
In order to estimate the economic impact of the Marfan
syndrome, a non-experimental, retrospective, population-
based matched cohort study design was applied. Costs for
Marfan syndrome patients were compared with those of a
matched cohort of patients not affected by the disease. The
analysis is based on administrative claims data from Tech-
niker Krankenkasse, Germany’s second largest sickness
fund (out of 221 sickness funds) covering about 9% of the
German population in 2008, i.e. 7.6 million insurees. The
dataset included longitudinal patient-level information on
socio-demographic status, direct (non-)medical costs as
well as on healthcare utilisation between 2006 and 2008,
such as employment status, costs for outpatient/inpatient
treatment or physician contacts.
We used a bottom-up, prevalence-based approach for
cost estimation. For the Marfan syndrome group, pa-
tients were required to have one inpatient ICD-10-GM
(German modification) Q87.4 diagnosis or at least two
outpatient Q87.4 diagnoses within 180 consecutive days
in 2006–2008 [36]. The control group was built by ran-
domly selecting up to 150 male and 150 female non-
Marfan syndrome insurees per each year of age (0 to
100 years) from the same database, i.e. 26,645 people.
Outcomes were measured in the observation period
between 1 January 2008 and 31 December 2008. In order
to allow for risk adjustment, a period of 365 days
(1 January 2007 to 31 December 2007) prior to the index
date (1 January 2008) was stipulated as the basis for de-
termining patient-level risk profiles. For each patient, an
ICD diagnosis was included in their risk adjustment if it
was made at least once in inpatient settings or at least
twice within 180 consecutive days in outpatient settings.
Hence, applying equally to the case and control groups,
individuals were excluded from the study if they had not
been constantly enrolled during the risk adjustment and
observation period. Patients who died during this time
frame are exempted from this imperative. Data mining
and cost analysis were conducted with SAS 9.3 (SAS In-
stitute Inc.) and R software respectively [37,38].
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Direct medical, direct non-medical and indirect costs
were estimated from the sickness fund and the societal
perspective. In order to achieve maximally transparent
and comparable results, costs were structured following
national standards into three distinct cost categories,
‘direct medical’, ‘direct non-medical’ and ‘indirect costs’
(see Table 1) [39].
Direct medical costs
First, direct medical costs are costs for inpatient/out-
patient treatments, care by non-physicians (e.g. physio-
therapy), pharmaceuticals, devices/medical appliances
(e.g. prostheses), rehabilitation and medical services (e.g.
home-based nursing care). Since the introduction of
§116b Social Code Book (SGB) V in 2006, accredited
hospitals can receive higher reimbursement prices for
treating Marfan syndrome patients in an outpatient set-
ting. Costs resulting from this funding scheme are de-
scribed separately. To adjust direct medical costs for the
societal perspective, co-payments for adult patients were
added for outpatient consultations, pharmaceuticals,
medical appliances, hospital stays and rehabilitations.
According to the legislation, total annual co-payments
were not allowed to exceed 1% of annual gross income







Devices and medical appliances
Rehabilitation






Informal care by family caregivers
Patient time (loss of leisure time)
Indirect costs
Reduced productivity at work
Lost production (absence, disability, premature death)
The first sign reflects the relevance of the cost item from the respective perspective
this analysis.
✓relevant | included; ✗ not relevant | not included; Ⓧ partially included.
acomprises patient co-payments in addition; bonly comprises costs borne by sickneresidual insurees. We used average wages in 2008 (men:
€39,528; women: €31,932) [40] to calculate sex-adjusted
co-payment thresholds according to §61 SGB V. The
value added tax (VAT) of 19% applicable to pharmaceu-
ticals and medical appliances was excluded in the soci-
etal perspective. Adding investment costs to the tune of
4.7% [41] of inpatient treatment costs was necessary
from the societal perspective to reflect the fact that hos-
pital investments are tax funded.
Direct non-medical costs
Second, direct non-medical costs from the sickness fund
perspective comprise administration costs, sick leave
compensation paid by the sickness fund, travel expenses
for physician appointments and ambulance transport as
well as other non-medical services (e.g. housekeeping).
Administration costs of €192 per insuree, based on the
average administration costs of all German sickness
funds, were applied [42].
Owing to the severe presentation of Marfan syndrome,
affecting not only patients but probably also their rela-
tives/partners [43], the cost of informal care by family
caregivers was included in the societal perspective. For
Marfan syndrome individuals under the age of 18 years,
we assumed that at least one family member was caring
for the person. Marfan syndrome patients over the ageectives
Perspective
Sickness fund Societal
✓| ✓ ✓| ✓a
✓| ✓ ✓| ✓a
✓| ✓ ✓| ✓
✓| ✓ ✓| ✓a
✓| ✓ ✓| ✓
✓| ✓ ✓| ✓
✓| ✓ ✓| ✓
✓| ✓ ✓| ✓
✓| ✓ ✗| ✗
✓| ✓ ✓|Ⓧb
✓| ✓ ✓|Ⓧb
✗| ✗ ✓| ✓
✗| ✗ ✓| ✗
✗| ✗ ✓| ✗
✗| ✗ ✓| ✓
, whereas the second sign reflects whether the item is included in
ss fund.
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if they were married or living with a partner (69.1%)
[44]. We did not incorporate care received from friends
or other relatives. As the number of hours per day that
carers spend with their Marfan syndrome-inflicted fam-
ily member/partner is unknown, we used literature on
family care for patients with heart diseases. Because of
the severe cardiovascular disease of Marfan syndrome
patients, we assumed that these patients require ap-
proximately the same amount of informal care as pa-
tients with a heart disease (8 hours per day, SD:
4.1 hours) [45]. In order to estimate the costs of infor-
mal care in the control group, we assumed that the mul-
tisystemic nature of Marfan syndrome, usually affecting
more than two organs/parts of the body, is comparable
to a health state of an individual with at least two dis-
tinct comorbidities. Control subjects who fulfilled the
criteria for at least two Elixhauser comorbidity groups
(measured by one binary variable per comorbidity class)
[46] were presumed to require the same amount of care
hours per day as Marfan syndrome patients. Subse-
quently, the carers’ hours spent on informal care, for
Marfan syndrome patients as well as for the control
group, were valued at the average annual gross wage in
2008 (€37,236) [40].
Sick leave compensations were excluded from the soci-
etal perspective as they denote a transfer payment.
Indirect costs
Being relevant from the societal perspective only, indir-
ect costs consist of the cost of absence from work, the
cost of premature death and the cost of reduced work
productivity. The last factor could not be incorporated
because our administrative data do not contain informa-
tion about fluctuations in productivity. As recommended
and widely applied [39,47], patient-level indirect costs
were measured using the human capital approach in the
baseline scenario. In a secondary analysis, we used the
friction cost model (see Table 2) [48].
The human capital approach measures production losses
in terms of lost earnings: in our case, the number of sick
leave days was multiplied by the average, sex-adjusted gross
annual wage including employer contributions to social in-
surance in 2008 (men: €44,748; women: €36,144) [40]. Ad-
justments for workforce participation (proportion of aTable 2 Overview of two approaches for measuring indirect c
Human capital approach (baseline analysis)




• measured through patient’s lost earnings (valued at 100%)
no cap on duration of absence from work
Premature
death
• value of lost hours of work (=earnings) that would have
accumulated until patient’s retirement agepopulation in the active labour force) and employment
rates were made. In the case of premature death, produc-
tion losses were accumulated until the average retirement
age of 65 years, adjusted for age- and gender-specific
workforce participation/unemployment rates [49], survival
probabilities [50], productivity growth (0.5%) [51] and dis-
counting (3%) [52].
In contrast, the friction cost approach accounts for
costs resulting from absence from work or premature
mortality only during the time it takes to replace the
missing worker. The time period until the worker is re-
placed is called the ‘friction period’ [48]. During the fric-
tion period itself (in Germany, 76 days [53]), the price of
labour is not valued at 100% because internal workers
can partially replace the missing individual and he/she
can make up for the lost production on returning to
work. Consequently, lost production was valued at 80%
[48] when the absence from work was shorter than the
average German friction period of 76 days [53]. If the
absence from work was longer than this, productivity
losses (at full value) were limited to 76 days, assuming
that the worker had been completely replaced afterwards
and the worker was not able to compensate for the for-
gone production. Premature death was treated as a fully
valued productivity loss of a complete friction period.
In general, all (non-)medical and (in-)direct costs were
winsorised (outliers are replaced by a specific percentile
value) at their lowest 1st and highest 99th percentiles at
cost category level in order to limit the distorting impact
of outliers.
Healthcare utilisation
Indicators for healthcare resource utilisation were con-
structed, including physician contacts, length of hospital
stays (LOS) and number of hospital stays, number and
average cost of prescriptions, number of magnetic reson-
ance (MRT)/computerised tomographies (CT) as well as
number of sick leave days.
Subgroup analysis and economic impact of Marfan
syndrome
Because disease manifestations and severity may pro-
gress throughout a patient’s lifetime, costs may differ
throughout the lifetime. To obtain a more granulated
picture of the cost distribution, the analysis was stratifiedosts
Friction cost approach (sensitivity analysis)
• considers patient’s hours of work that are lost until employer can
replace the patient
• measured through patient’s lost earnings (valued at 80%) absence
from work capped at 76 days (friction period)
• value of lost hours of work (=earnings) + value of lost hours of work
for a full friction period (valued at 100%)
Figure 1 Overview of the steps in the statistical
analysis/matching procedure.
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population (I: 0–16 years, II: 17–24 years, III: 25–41
years, IV: >41 years).
We estimated the economic impact by multiplying the
excess costs of Marfan syndrome by the number of dis-
eased people in Germany. In addition to using preva-
lence rates obtained from our data, we used prevalence
rates from the literature. According to international esti-
mations, prevalence rates range from 1 [54] to 3 [2] per
10,000.
Statistical analysis
The aim of this paper is to isolate the specific effect of
Marfan syndrome on costs – the so-called ‘average treat-
ment effect on the treated’ (ATT) [55]. However, obser-
vational studies may be subject to selection bias and to
unbalanced population baseline characteristics because
of a lack of randomisation. Thus, in order to reduce con-
founding due to unbalanced baseline characteristics be-
tween the Marfan syndrome patients and the control
group as well as to determine the excess costs (ATT) of
Marfan syndrome, ‘genetic matching’ (GM) was applied.
GM is a multivariate algorithm that matches Marfan
syndrome patients with their most similar control sub-
jects on a set of observed covariates (e.g. age, sex, co-
morbidity). GM significantly improves the comparability
of group baseline characteristics [56]. After GM, the dif-
ference in costs between the Marfan syndrome patients
and the control group, i.e. excess costs, represents
the effect specifically attributable to Marfan syndrome
(ATT) [57].
Prior to applying GM, it is necessary to specify the covari-
ates to match on. To minimise bias, we used a list of pre-
specified variables that are considered to possess a high
prognostic potential for the outcome (cost). Evidence
suggests that gender, age [58], comorbidities [46] and
pharmacy-based metrics (PBM) [59] are robust predictors
of healthcare costs. Consequently, in the matching proced-
ure, the covariates were sex, age, 29 of the total 31 Elixhau-
ser comorbidity groups [46,60] and 30 of the total 32 PBM
groups [59]. We excluded two Elixhauser comorbidity
groups (‘mitral valve disease’, ‘aneurysms’) and two PBM
groups (‘blockers/calcium channel blockers’, ‘ACE inhibi-
tors/angiotensin II antagonists’) which are directly related
to Marfan syndrome. All covariates were determined in
2007.
First, using a logistic regression, a propensity score (PS)
[61] was obtained by combining the above-mentioned co-
variates (sex, age, 29 Elixhauser comorbidity groups and 30
PBM groups). Subsequently, a one-to-one GM was run to
attain balance on the PS, age and sex (see Figure 1). We ap-
plied GM with replacement as it will generally achieve the
best balance on covariates and the smallest conditional bias
[57]. In order to compare the balance of covariates beforeand after matching, bootstrap Kolmogorov–Smirnov (KS)
tests and empirical quantile–quantile (eQQ) statistics were
calculated [62].Sensitivity and secondary analyses
The statistical significance (p-values) of the matching re-
sults is only valid under the assumption that there are
no unobserved confounders. Hence, Rosenbaum bounds
were computed to estimate the impact of potentially
existing hidden bias from unobserved covariates [63,64].
Rosenbaum bounds give an indication of how strong a
hidden bias (Γ) must be such that it changes the infer-
ence about the causal effects from the matching proced-
ure [64]. In sum, a model is insensitive to hidden bias if
its conclusions change for large values of Γ, whereas it is
sensitive if its conclusions alter for values that are only
slightly larger than Γ =1.
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logical and structural specifications, three further ana-
lyses were conducted. First, we applied a pure PS model
with the same parameterisations, but without the GM al-
gorithm [65]. Second, the friction cost approach for esti-
mating indirect costs was applied. Third, we carried out
a sensitivity analysis on the lower-bound amount of
hours for informal family care by subtracting one stand-
ard deviation from the mean (8–4.1 = 3.9 h/day).
Results
In total, 892 individuals with Marfan syndrome and
26,645 control subjects were included. The prevalence of
Marfan syndrome was 1.17 per 10,000 individuals within
the population of Techniker Krankenkasse. These 892
Marfan syndrome patients were matched one-to-one with
892 control individuals. Overall, the GM drastically reduced
differences in all baseline covariates (see Table 3). The mean
age of the control group was reduced from 50.50 years to
28.90 years, removing statistical difference to the Marfan
syndrome group (28.95 years). Similarly, the predominance
of males was diminished to 40.70% in order to adjust to the
Marfan syndrome group. The difference in the PS between
the groups was no longer statistically different from zero
(p = 0.999) after GM. Although the two groups hadTable 3 Baseline characteristics of the Marfan syndrome
patients and control group and balancing tests pre and
post genetic matching
Variables Marfan Control aD-statistic bp-value
Sample size (N)
before matching 892 26,645 – –
after matching 892 892 – –
Mean age (years)
before matching 28.95 50.50 0.389 <0.001
after matching 28.95 28.90 0.002 0.996
% female
before matching 40.70 50.45 – <0.001
after matching 40.70 40.70 – 1
Mean propensity score
before matching 0.116 0.029 0.470 0.002
after matching 0.116 0.116 0.002 0.999
Elixhauser comorbidities
before matching 15 of 29 significantly different at p < 0.05
after matching 0 of 29 significantly different at p < 0.05
Pharmacy-based classes
before matching 16 of 30 significantly different at p < 0.05
after matching 0 of 30 significantly different at p < 0.05
aD-statistic represents the maximum difference in the empirical cumulative
distribution function (eQQ statistic).
bp-value: paired t-test for dichotomous and KS test for continuous variables.statistically significant differences (at p < 0.05) prior to
matching in 15 of 29 Elixhauser groups, and in 16 of 30
PBM groups, the GM has removed all these divergences
and has created a highly balanced distribution of clinical
baseline characteristics (see Table 3 and Additional file 1:
Table A1).Sickness fund perspective
In both cost study perspectives, Marfan syndrome pa-
tients entail statistically significant higher costs (see
Table 4). From the sickness fund perspective, an average
Marfan syndrome patient generates higher direct
medical costs (€2330, p < 0.001) and greater direct non-
medical costs (€167, p < 0.001) than an average non-
Marfan syndrome patient, resulting in total excess
expenditure of €2496 (p < 0.001). Inpatient treatment
(38.4%), care by non-physicians (33.8%), outpatient
visits (10.7%) and pharmaceuticals (5.8%) constitute the
greatest share of the total difference. In our data, 28 pa-
tients were treated within the reimbursement frame-
work of §116b SGB V, which resulted in average costs of
€2954 per patient per year. In total, the costs of medical
services reimbursed through §116b as a share of the
cost of all hospital treatments was 6.9%. Sick leave com-
pensations represent the largest cost block in the direct
non-medical costs with an excess of €143 (p < 0.001).
These costs are directly related to the increased number
of sick leave days taken by Marfan syndrome patients
(9.23 vs. 5.02, p < 0.001).Societal perspective
From the societal perspective, Marfan syndrome patients
generate excess costs to the tune of €15,728 (p < 0.001).
The surplus in direct medical costs (€2366, p < 0.001) dif-
fers only slightly from the sickness fund perspective. How-
ever, excess direct non-medical costs are substantially
higher at €5875 (p < 0.001) and represent 37.4% of the total
excess costs. This is primarily caused by the introduction of
costs for informal care by family caregivers (€5851, p <
0.001), which are considerably higher for the Marfan syn-
drome group (€7200) than for the control group (€1349).
In addition, indirect costs for lost production come into
play with a surplus of €7487 (p < 0.001).Healthcare utilisation
In terms of healthcare utilisation, Marfan syndrome pa-
tients had 38.8% more physician contacts (p < 0.001), a
153.3% longer average length of stay if hospitalised (p <
0.001), 119.0% more inpatient stays (p < 0.001), 33.4%
more prescriptions (p < 0.001), 236.3% more MRTs/CTs
(p < 0.001) and 19.7% higher average prescription costs
than control individuals (see Table 4).
Table 4 Average treatment effects for the treated (excess costs) in € (per capita, in 2008)
Sickness fund perspective Societal perspective
Marfan Control ATTa AI SEb Marfan Control ATTa AI SEb
Direct medical costs 4024 1695 2330 *** 273 4105 1739 2366 *** 278
Outpatient treatment 780 512 268 *** 35 800 531 269 *** 35
Pharmaceuticals 385 241 145 ** 46 349 222 127 ** 39
Care by non-physicians 1315 472 843 *** 163 1353 501 851 *** 165
Devices and medical appliances 142 76 66 *** 18 122 65 57 *** 15
Inpatient treatment 1337 379 958 *** 164 1413 403 1010 *** 173
Rehabilitation 66 14 52 *** 15 67 14 53 *** 16
Medical services <1 1 −1 5 <1 1 −1 2
Direct non-medical costs 392 226 167 *** 36 7431 1556 5875 *** 116
Administration 192 192 0 0 192 192 0 0
Sick leave compensation 161 18 143 *** 34 n/a n/a n/a n/a
Travel expenses 39 15 24 *** 7 39 15 24 ** 9
Other non-medical services <1 <1 <1 <1 <1 <1 <1 <1
Informal family care n/a n/a n/a n/a 7200 1349 5851 *** 116
Indirect costs n/a n/a n/a n/a 10,329 2842 7487 *** 718
Total costs 4416 1920 2496 *** 286 21,865 6137 15,728 *** 824.4
Indicators for healthcare utilisation
Sick leave days 9.23 5.02 4.21 *** 1.11
Physician contacts 10.11 7.28 2.83 *** 0.26
Average length of stay 3.06 1.21 1.85 *** 0.52
Inpatient stays 0.39 0.18 0.21 *** 0.04
Prescriptions 8.70 6.52 2.18 *** 0.49
Average prescription cost 27.58 23.04 4.55 3.61
MRT/CT imaging 0.37 0.11 0.26 *** 0.05
aaverage treatment effect for the treated represents excess resource utilisation attributable to Marfan.
bAbadie–Imbens standard errors take the uncertainty of the matching process into consideration [57].
**< 0.01 ***< 0.001.
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Total costs per year of age from the sickness fund per-
spective are depicted in Figure 2. Because the frequency
of Marfan syndrome patients in our study group below
the age of 5 years and above the age of 60 years is low,
as represented by the shaded area in the scatterplot, reli-
able estimates can be drawn only for age quartiles or for
the population between the ages of 5 and 60 years. For
instance, the great cost difference in children up to the
age of 5 years results from three outliers that incurred
exceptionally high costs for physiotherapy. The third age
quartile (25–41 years) reveals the greatest surplus in
total costs (€2711), followed by the first (0–16 years,
€2322) and fourth (>41 years, €2209) quartiles (see
Additional file 1: Table A2). For quartile III, the main ex-
cess cost drivers are direct medical costs (€2394) includ-
ing inpatient treatment (€1434), care by non-physicians
(€492) and outpatient visits (€282). In the lowest age
quartile (0–16 years), care by non-physicians (€1061),inpatient (€811) and outpatient treatments (€222) are
the major cost blocks of excess direct medical costs
(€2311). From the societal perspective, the second (17–
24 years: €27,636) and third quartiles (€15,146) cause
the greatest excess expenditure. This is mainly a result
of the high costs of lost production due to premature
death in young to middle-aged individuals. Excess costs
of informal care by family caregivers are highest in the
youngest group (QI: €9121) because children receive
more family care than middle-aged individuals according
to our model specifications. However, no production
losses accrue to children.
Economic impact of Marfan syndrome
Given a German population of 82.002 million in 2008 and
depending on the prevalence rates (1.17–3/10,000), 9600 to
24,600 individuals are expected to have Marfan syndrome.
Applying the cost data from our study, the overall cost of
disease in 2008 from the sickness fund perspective ranged
Figure 2 Total costs per capita for Marfan syndrome patients and control individuals, from the sickness fund perspective.
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extended from €151.4 to €386.9 million.
Results from sensitivity analysis
The Rosenbaum bounds test reveals that our results are
highly robust to potentially existing unobserved con-
founders (see Additional file 1: Table A3). The lower and
upper p-value bounds show whether unobserved con-
founders of the magnitude Γ have an influence on our re-
sults. For most outcome parameters, even a very strong
hidden bias of the magnitude Γ =3 has no influence on the
inference of the matching (at p < 0.05). Concerning phar-
maceuticals, for instance, at a magnitude of bias of Γ = 2.5,
one would not be able to reject the hypothesis (pU = 1) that
unobserved covariates have an impact on the conclusions
of the matching. Hence, at Γ = 2.5, the excess drug costs
might not be a causal effect of Marfan syndrome but pos-
sibly result from unobserved confounders.
Matching with a PS model instead of GM did not lead to
substantially different results, showing that our model is ro-
bust to different specifications of the matching algorithm.
As anticipated, replacing the human capital approach with
the friction cost model to value the costs of lost production
considerably reduced the excess indirect costs to €359
(−95.26%), with highest excess values in the third age quar-
tile (€999). Overall, the friction cost model yields an ATT
of total costs of €8599, which is 44.24% lower than that in
the baseline scenario (see Table 5).
Decreasing the amount of daily hours of family care-
giving to 3.9 h diminished Marfan syndrome patients’
excess costs for informal family care from €5875 to
€2852 (p < 0.001). Consequently, the total societal cost
difference amounted to €12,729 (p < 0.001) compared
with €15,728 in the baseline scenario.
Discussion
To the knowledge of the authors, this is the first study
worldwide to representatively examine the economicimpact attributable to Marfan syndrome across in/out-
patient sectors from a sickness fund and societal perspec-
tive with claims data. The analysis used a dataset with a
large sample of insurees and a detailed account of costs and
health resource utilisation. The demographic structure of
the insurees in this dataset is representative of the overall
German population [66]. A powerful matching algorithm
(‘genetic matching‘) was applied to balance observable con-
founders and to extract the causal effect of Marfan syn-
drome on costs. In contrast to other cost-of-illness studies,
which simply total all medical or diagnosis-related costs
without a comparison group, the reliability of our results is
high because we identified the excess costs that are specific-
ally attributable to Marfan syndrome [67].
From a sickness fund and societal perspective, the aver-
age excess expenditure per Marfan syndrome patient in
2008 was €2496 and €15,728 respectively. Costs mainly re-
sulted from inpatient stays, care by non-physicians, out-
patient treatments as well as informal family care and
production losses in the societal perspective. Although
Marfan syndrome patients required higher incremental
drug expenditure (sickness fund: €145), the difference was
not large because the most frequently applied pharmaco-
logical therapy for Marfan syndrome – beta-blockers [68] –
is relatively inexpensive.
Cost differences between Marfan syndrome and control
subjects were highest in the third (25–41 years) and first
(0–16 years) age quartiles from the sickness fund perspec-
tive. These results agree with the characteristics and pro-
gressive development of the disease. On the one hand,
childhood and adolescence are regarded as the decisive
period for the development of cardiovascular diseases in
Marfan syndrome [69]. Hence, costs for Marfan syndrome
patients in their early years of life may most likely be ele-
vated because their diagnosis needs to be established using
costly methods including FBN1 gene sequencing, regular
cardiovascular check-ups, ophthalmological care [8] and
potentially life-long pharmacological therapy [1]. Their high
Table 5 Sensitivity and secondary analyses with propensity score matching and friction cost model (values per capita
in 2008)
Baseline (GM) PS model Friction cost model
ATTa (in €) ATTa (in €) % changeb ATTa (in €) % changeb
Sickness fund perspective
Direct medical costs 2330 2024 −13.14 2330 0
Direct non-medical costs 167 161 −3.58 167 0
Total costs 2496 2184 −12.49 2496 0
Societal perspective
Direct medical costs 2366 2059 −12.97 2366 0
Direct non-medical costs 5875 5790 −1.44 5875 0
Indirect costs 7487 7573 1.15 359 −95.26
Total costs 15,728 15,422 −1.95 8599 −44.24
aaverage treatment costs of the treated (ATT) represent excess costs attributable to Marfan.
bpercentage change compared with baseline GM model.
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need to treat skeletal malfunctions, such as physiotherapy
for scoliosis or pectus deformities [8,43,70]. In addition,
costs in the youngest quartile might be driven by newborns
with the severe manifestation of the disease or by the neo-
natal Marfan syndrome [33]. Most of these infants have a
life expectancy of less than 1 year of age and are highly
treatment intensive [71]. On the other hand, patients in the
third age quartile have to cope with symptoms of Marfan
syndrome that have been aggravated over time. Cardiovas-
cular manifestations often do not become overt and diag-
nosed until the third decade of life [10]. By that time,
progressive aortic dilatation and aneurysms often dictate
aortic and mitral valve surgery [68,72]. As shown in a re-
cent meta-analysis, the mean age of Marfan syndrome pa-
tients undergoing cardiac surgery lies somewhere in their
early/mid-thirties [14]. Our data corroborate this finding,
indicating that inpatient stays, mostly because of cardiovas-
cular surgeries, constitute 59% (€1434) of the excess direct
medical costs in the third age quartile.
Owing to the systemic nature of their disease, Marfan
syndrome patients require significantly more healthcare
resources than control subjects, such as prescriptions,
physician visits and inpatient stays/duration. Depending
on the prevalence rate, the total economic impact ranges
between €24.0 and €61.4 million (sickness fund perspective)
and €151.3 and €386.9 million (societal perspective). Owing
to the high number of sick leave days, Marfan syndrome
has a considerable impact on employability.
Putting this study into the context of the scientific lit-
erature is challenging because, so far, very little evidence
exists on the cost of illness of Marfan syndrome. Unre-
stricted comparisons cannot usually be made across dif-
ferent cost-of-illness studies on account of diverging
methodologies [67], such as total cost vs. incremental/
excess cost studies. One German micro-costing study
without a control group estimated that the averagedirect medical cost – measured by resource consump-
tion – of treating a Marfan syndrome patient in their
specialised outpatient clinic in 2008 amounted to €389
[34]. This figure is lower than our result (€780) because
costs that accrued at other in/outpatient sites, such as
expensive genetic testing, were not incorporated in that
study [34]: in practice, however, the numerous morbid-
ities of Marfan syndrome compel patients to see differ-
ent in/outpatient specialist clinics, such as orthopaedics,
ophthalmology and cardiology.
In terms of studies examining other rare diseases with
a similar methodology, Blankart et al. (2013) [73]
showed that costs attributable to chronic lymphocytic
leukaemia (CLL) amounted to €4946 from a sickness
fund perspective and €7910 from a societal perspective.
In comparison with common chronic diseases, such as
diabetes (€19,677 m in 2010) [74], the attributable
societal costs of Marfan syndrome are relatively low
(€386 m in 2008) because of its rare occurrence (1–3/
10,000). Nonetheless, considering that the costs and
prevalence of Marfan syndrome constitute a fraction of
1.97% of the costs and 0.34% of the prevalence of dia-
betes (890/10,000) [75], it becomes clear that the eco-
nomic impact per Marfan syndrome patient is nearly six
times higher than the impact per diabetes patient.
Limitations
We see four limitations to our study. First, although admin-
istrative data provide a comprehensive picture of healthcare
costs and are increasingly recognised in health services and
epidemiological research [76,77], our data do not provide
any information on the clinical progression and/or severity
of disease. For instance, neonatal Marfan syndrome or spe-
cific mutations in the FBN1 gene [12] may be more severe
than other forms of Marfan syndrome, e.g. a manifestation
of ectopia lentis and skeletal abnormalities. Consequently,
healthcare resource utilisation and expenditure may vary
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mental stages/severities of Marfan syndrome would be a
factor worth considering in future research. Furthermore,
our data do not include information about costs relating to
public welfare budgets, such as costs for pension funds. An-
other pitfall of administrative data is the usage of the ICD
catalogue, where some disorders similar to Marfan syn-
drome, such as the Shprintzen–Goldberg syndrome, may
not be coded correctly because the current ICD classifica-
tion includes only codes for about 500 out of the 8000
named rare diseases [78]. However, we believe that those
ultra-rare diseases (estimated prevalence of Shprintzen–
Goldberg syndrome is less than 50 cases in Europe [79]),
which might be coded incorrectly, do not substantially bias
our results.
Second, although the costs of genetic testing for FBN1
mutations were included in the inpatient sector (through
§116b reimbursement), it was not possible to account
for them in the outpatient sector. Data coding modalities
did not allow us to measure genetic testing costs for 20
Marfan syndrome patients. Such genetic testing, how-
ever, can be very expensive. Therefore, we might slightly
underestimate outpatient treatment costs.
Third, we were not able to quantify intangible dimensions
of indirect costs. For instance, Marfan syndrome patients
face significant restrictions with respect to their quality of
life, such as chronic pain [80] or psychological distress
[44,81], which may in turn affect productivity [82,83]. Simi-
larly, because of an absence of information on treatment
schedules/time spent coping with Marfan syndrome, pa-
tients’ loss of leisure time was not included.
Finally, the inferences from the matching rely on the as-
sumption that all relevant covariates have been included
and that no unobserved confounders exist (‘unconfounded-
ness assumption’) [84]. This assumption is not empirically
testable because hidden confounders cannot be measured.
Nonetheless, one can assess the plausibility of the ‘uncon-
foundedness assumption’ by measuring the impact of the
hypothetical existence of hidden confounders on the infer-
ences, as we did using Rosenbaum bounds. Our results sug-
gest that unconfoundedness is plausible because hidden
bias (Γ) had little impact on outcomes.
Conclusion
Relative to its low frequency, the treatment of Marfan
syndrome requires high healthcare expenditure. Not
only the high costs of Marfan syndrome but also its
great burden on patients’ lives call for more awareness
from policy-makers, physicians and clinical researchers.
Early diagnosis and prophylactic treatment may limit
cardiovascular complications in particular and thus con-
tain healthcare expenditure and patient morbidity. Use
of health information technology, such as patient
medical records, and enhanced coordination amonghealthcare providers across sectors might improve the
medical management of rare diseases [85,86]. Finally,
knowledge about the pathogenesis of the disease is in-
creasingly being gained, and it is expected that the ac-
complishments of translational research in molecular
biology will soon open a window of opportunity for
treating most systemic manifestations of Marfan syn-
drome [24].
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